Predictors of outcomes with CD3 x CD20 bispecific antibodies after CAR-T failure in B-cell lymphoma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-02-03
Просмотров: 212
Описание:
Megan Melody, MD, Cancer Center of South Florida, Palm Springs, FL, comments on the efficacy and predictors of outcomes with CD3 x CD20 bispecific antibodies post-CAR T-cell failure for aggressive B-cell lymphoma. Dr Melody highlights several patient and disease characteristics of those at a higher risk of not responding to bispecific antibodies and emphasizes that survival following progression of disease after bispecific antibodies in the post-CAR T-cell setting is quite dismal. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
